Compared with patients randomized to usual care , full coverage patients adherent to statin , - blocker , or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker were significantly less likely to experience the study 's primary outcome ( hazard ratio [ HR ] range 0.64-0 .81 ) .